VPG Awarded FDA Grant to Develop Clinical Outcome Assessments for Migraine

As part of our Patient Focused Drug Development (PFDD) efforts, the U.S. Food and Drug Administration (FDA) developed a pilot grant program to support the development of publicly available core set(s) of Clinical Outcome Assessments (COAs) and their related endpoints for specific disease indications (RFA-FD-19-006). On September 11, 2019 the FDA made three awards under this grant program. These awards will provide avenues to advance the use of patient input as an important part of drug development that can foster innovation and … Read More